Addition of pramlintide to insulin therapy lowers HbA1c in conjuction with weight loss in patients with type 2 diabetes approaching glycaemic targets

Diabetes, Obesity and Metabolism

Volumn 5, Issue 6, 2003, Pages 408-414

  Hollander, P ^a   Ratner, R ^b   Fineman, M ^c   Strobel, S ^c   Shen, L ^c   Maggs, D ^c   Kolterman, O ^c   Weyer, Christian ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Pramlintide; Type 2 diabetes; Weight loss

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; SULFONYLUREA;

ANOREXIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

EID: 0345328762     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00295.x     Document Type: Article

References (33)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
2. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control on metformin with complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
3. UK Prospective Diabetes Study Group. Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylureas, metformin, or insulin in patients with type 2 diabetes mellitus (UKPDS 49). JAMA 1999; 281: 2005-2012.
5. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
6. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-768.
7. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 1996; 19: 744-750.
8. Nathan DM, McKitrick C, Larkin M, Schaffran R, Singer DE. Glycemic control in diabetes mellitus: Have changes in therapy made a difference? Am J Med 1996; 100: 157-163.
9. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7: 1353-1373.
10. Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE. Amylin response following Sustacal® ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia 1996; 39: A149 [Abstract 566].
11. Young AA. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes 1997; 4: 282-290.
12. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997; 46: 67-70.
13. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995; 38: 642-648.
14. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther 2002; 4: 175-189.
15. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002; 20: 137-144.
16. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 1997; 14: 547-555.
17. Maggs DG, Fineman M, Kornstein J et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: A dose-timing study. Diabetes Metab Res Rev (in press).
18. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 9: 504-508.
19. Lee JS, Vella A, Camilleri M et al. Vagal inhibition in the retardation of gastric emptying of solids by the amylin analog, pramlintide, in diabetes mellitus. Gastroenterology 2000; 118: A624.
20. Hollander PA, Levy P, Fineman M et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: A one year randomized controlled trial. Diabetes Care 2003; 26: 784-790.
21. Gottlieb A, Fineman M, Bahner A, Parker J, Waite G, Kolterman O. Pramlintide therapy in addition to insulin in type 2 diabetes: Effect on metabolic control after 6 months. Diabetologia 1999; 42 (Suppl. 1): A232 (Abstract 873).
22. Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51-61.
23. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patient. Variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-885.
24. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450-459.
25. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Tech Ref Series 2000, No. 894, Geneva.
26. Riddle MC. Should obese type 2 diabetic patients be treated with insulin? In: Gill GV, Pickup JC, Williams G eds. Difficult Diabetes. Oxford: Blackwell Science, 2001; 94-112.
27. Purnell J, Weyer C. Weight effect of current and experimental diabetes drugs: From promotion to alleviation of obesity. Treat Endocrinol 2003; 2: 23-37.
28. American Diabetes Association Position Statement. Standards of care for patients with diabetes mellitus. Diabetes Care 2003; 26: S33-S50.
29. Del Prato SD. In search of normoglycaemia in diabetes: Controlling postprandial glucose. Int J Obes 2002; 26 (Suppl. 3): S9-S17.
30. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: Metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45: 461-475.
31. Rushing PA, Hagan MM, Seeley RJ et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 2001; 142: 5035-5038.
32. Morley JE, Flood JF. Amylin decreases food intake in mice. Peptides 1991; 12: 865-869.
33. Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake and Obesity. Obesity Research; 2002; 10: 1087-1091.